CClinicalTrials.gg
CompletedNCT03861663Updated Mar 4, 2019

Venue Ultrasound Evaluation - Israel

An interventional study of Ultrasound in Ultrasound Exam in Emergency/Medical Care, sponsored by GE Healthcare. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-04.

Sponsored by GE Healthcare · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2017, registered Mar 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study purpose is to collect images and user feedback from the Next Generation Venue Ultrasound system, components, and accessories under clinical conditions, as required for device development and optimization.

Read the detailed description

Adult patients (aged >18 years) will be enrolled that present for emergency or immediate medical care, in facilities such as the intensive care unit (ICU), US unit, and/or other departments. Subjects may or may not have a clinical indication for ultrasound scanning as part of their regular medical care and will be required to meet the inclusion criteria and none of the exclusion criteria. If a subject has a clinical indication for ultrasound exam, the routine exam will be performed with the standard equipment, and an additional exam will be performed using the investigational ultrasound device.

02

Conditions studied

  • Ultrasound Exam in Emergency/Medical Care

Browse trials for

03

In context

Emergencies

1,692 studies on the registry are indexed under Emergencies; 333 are open to participants now.

This study's enrollment of 53 is below the median of 145 across 931 interventional studies indexed under Emergencies.

Browse Emergencies studies →

Lead sponsor

GE Healthcare is the lead sponsor of 168 studies on the registry; 19 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adults (aged 18 years of age or older) at the time of consent;
  2. Eligible to undergo ultrasound scanning per the site standard of care (with or without a clinical indication for scanning);
  3. Able and willing to provide written informed consent for participation

Exclusion criteria

Exclusion Criteria:

  1. Are pregnant subjects
  2. Require procedures that cannot be readily completed using available investigational devices;
  3. Require or are anticipated to require medical care where study participation could reasonably be expected to adversely impact patient care.
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Other
    Eligible Subjects

    All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.

    Device: Ultrasound

Interventions

  • DeviceUltrasound

    Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.

06

What researchers measure

Primary outcomes

  1. Obtain Image sets using Ultrasound Venue System

    Number of representative image sets for subjects enrolled in study

    Time frame: Two months

  2. Periodic user feedback

    Periodic user feedback data (Clinician User Preference Survey) from device users on device performance for quality optimization. The feedback will not be aggregated or statistically analyzed. The scale is a 1-5 Likert score (1 - Poor, 2 - Needs Improvement, 3 - As expected/Equal, 4 - Better then expected, 5 - Excellent) There is no total score.

    Time frame: Two months

07

Study locations

1 site
  • Rambam Health Care Center
    Haifa, 3109601, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03861663
Lead sponsor
GE Healthcare
Collaborators
Rambam Health Care Campus
Responsible party
Sponsor
First posted
Mar 4, 2019
Start date
Dec 1, 2017
Primary completion
Jan 29, 2018
Completion
Jan 29, 2018
Last update
Mar 4, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion